Retinal Biologics Market to Reach USD 41.92 Billion by 2028, Driven by Robust CAGR of 11.1%

Global Retinal Biologics Industry
Global Retinal Biologics Market

The global retinal biologics market continues its impressive growth trajectory, with market revenue reaching USD 19.96 billion in 2021. According to recent industry analysis, the market is projected to nearly double by 2028, achieving a valuation of USD 41.92 billion at a compound annual growth rate (CAGR) of 11.1% between 2022 and 2028.

This rapid growth underscores the increasing demand for advanced biologic therapies to treat retinal disorders, such as age-related macular degeneration (AMD), diabetic retinopathy, and other vision-threatening conditions. The rising prevalence of these diseases, coupled with advancements in biotechnology and a growing emphasis on personalized medicine, is fueling market expansion.

Key Market Drivers:

  • Growing incidence of retinal diseases due to aging populations worldwide.
  • Rising adoption of innovative biologic treatments over conventional therapies.
  • Increased investments in research and development for ophthalmology biologics.

Competitive Landscape

Several companies are entering into licensing and collaboration agreements to expand their products into various countries across the world to cater to unmet demand. Leading market players are concentrating their efforts on research & development to discover new medications and improve treatment options.

For instance,

  • In 2021, SemaThera Inc. and Roche established a multi-year research and licensing relationship to expand SemaThera’s novel biologics portfolio for the treatment of ischemic retinal illnesses such as diabetic retinopathy.

Key Companies Profiled

Spark Therapeutics, Inc.; F. Hoffmann-La Roche Ltd.; Regeneron Pharmaceuticals, Inc.; AbbVie Inc.; Amgen Inc.; Novartis Pharma AG; MeiraGTx Limited; Oxurion NV; Santen Pharmaceutical Co., Ltd.; Bayer AG; Bausch Health Companies Inc.; Merck & Co., Inc.

Key Segments of Retinal Biologics Industry Survey

Retinal Biologics Market by Drug Class:

  • VEGF-A Antagonists
  • TNF-α Inhibitors

Retinal Biologics Market by Indication:

  • Macular Degeneration
  • Diabetic Macular Edema
  • Diabetic Retinopathy
  • Uveitis
  • Others

Retinal Biologics Market by Distribution Channel:

  • Institutional Sales
  • Retail Pharmacies
  • Mail Order Pharmacies
  • Retail Sales

Retinal Biologics Market by Region:

  • North America Retinal Biologics Market
  • Latin America Retinal Biologics Market
  • Europe Retinal Biologics Market
  • East Asia Retinal Biologics Market
  • South Asia & Pacific Retinal Biologics Market
  • Middle East & Africa (MEA) Retinal Biologics Market

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

About the Author

Nikhil Kaitwade

Associate Vice President at Future Market Insights, Inc. has over a decade of experience in market research and business consulting. He has successfully delivered 1500+ client assignments, predominantly in Automotive, Chemicals, Industrial Equipment, Oil & Gas, and Service industries.
His core competency circles around developing research methodology, creating a unique analysis framework, statistical data models for pricing analysis, competition mapping, and market feasibility analysis. His expertise also extends wide and beyond analysis, advising clients on identifying growth potential in established and niche market segments, investment/divestment decisions, and market entry decision-making.
Nikhil holds an MBA degree in Marketing and IT and a Graduate in Mechanical Engineering. Nikhil has authored several publications and quoted in journals like EMS Now, EPR Magazine, and EE Times.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these